CJC-1295 (DAC)
CJC-1295 With DAC (5mg)
$100USD
Third-Party Tested
Independent lab verified
Batch-Specific CoA
Publicly accessible
YPB.220
Reference number
5mg
Lyophilized vial
Modified GHRH analog with Drug Affinity Complex for extended half-life. Binds covalently to albumin, prolonging activity.
Origin
CJC-1295 with DAC was developed by ConjuChem Biotechnologies as a long-acting growth hormone-releasing hormone analog. The Drug Affinity Complex (DAC) technology covalently attaches the modified GRF(1-29) peptide to circulating albumin in vivo, dramatically extending its half-life from minutes to days.
Research Lineage
Teichman et al. published Phase I/II clinical trial results in 2006, demonstrating sustained GH and IGF-1 elevation for up to two weeks following a single injection. ConjuChem's DAC platform represented a novel approach to peptide drug delivery. The compound has been studied for GH axis modulation and age-related GH decline research.
Mechanism of Action
The DAC moiety contains a reactive group that forms a covalent bond with Cys34 of serum albumin after subcutaneous administration. Once conjugated, the peptide circulates with albumin (half-life ~14 days), providing continuous GHRH receptor stimulation. This results in a sustained, non-pulsatile elevation of GH levels — distinct from the pulsatile pattern seen with the non-DAC version.
Structural Notes
Modified GRF(1-29) conjugated to a maleimidopropionic acid-based DAC linker. Total molecular weight: ~3647 Da (peptide + linker, pre-conjugation).
Key References
Teichman SL et al. J Clin Endocrinol Metab. 2006;91(3):799-805.
Research Use Only. This product is intended for laboratory research purposes only. Not for human or veterinary use. Not for sale to minors.